Collegium Pharmaceuticals (COLL +30.9%) is up on more than a 4x surge in volume in early trade in reaction to its Q3 results released after the close yesterday. Highlights:
Revenues: $72.9M (+4%).
Sales of Xtampza ER (oxycodone) extended-release capsules up 56% to $26.5M (+2% sequentially), prescriptions up 44%.
Net loss: ($6.1M) (+63%); loss/share: ($0.18) (+64%).
Non-GAAP net income: $1.7M (+121%).
Effective January 1, 2020, Xtampza ER will have exclusive formulary positions across 15 healthcare plans covering more than 35M additional lives (up from 50M presently).
Previously: Collegium Pharmaceutical EPS misses by $0.03, misses on revenue (Nov. 6)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.